Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Meetings

Virtual Education Program

  • Presentations from the EHA2022 Congress

    Watch here

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

    Watch here

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

    Watch here

  • COLT Meeting 2019: CML related topics

    Watch here

  • COLT Meeting 2019: The CML frontier

    Watch here

    EHA 2019: The future of CML therapy: unmet medical needs and new treatments in development (Michael Mauro)

    Michael Mauro EHA 2019

     

    The Future of CML Therapy: Unmet Medical Needs and New Treatments in Development
    Professor Michael Mauro, Memorial Sloan Kettering Cancer Center New York, USA 

    • Unmet needs in CML: TKI and SCT
    • TKI's in development for CML
    • Development of Asciminib for CML
    • ABL 001X2101: A multicenter, phase 1, first-in-human study
      •  Allosteric inhibition of BCR-ABL
      •  ABL 001X2201: T315l cohort
      • Asciminib phase 3 study Design NCT 03106779
      • Asciminib Phase 2 study design:
        Add-on to first-line imatinib for DMR NCT 03578367
    • PF-114: 3rd generation BCR-ABL
     

    This talk was first presented at EHA during the Satellite Symposium: 'Optimizing patient outcomes in CML and classical MPN's: New treatment paradigms and future developments' - supported by Incyte. You will find more education materials from EHA at the EHA Learning Centre.